Published in Brain Res on December 22, 1978
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology (2005) 1.75
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci (2001) 1.72
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience (1989) 1.64
Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord (1991) 1.62
Source localisation of 62-electrode human laser pain evoked potential data using a realistic head model. Int J Psychophysiol (2001) 1.39
Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry (1997) 1.38
The clinical and surgical feature in 40 patients with primary cerebellar ectopia (adult Chiari malformation). Q J Med (1977) 1.37
Problems associated with iontophoretic studies in the caudate nucleus and substantia nigra. Neuropharmacology (1974) 1.37
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J (2000) 1.32
Experimental hemichorea/hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia. Brain (1984) 1.14
Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia (1993) 1.12
Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience (1987) 1.04
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology (2001) 1.03
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol (2000) 1.00
Further evidence for the stimulation of rat brain dopamine receptors by a cyclic analogue of dopamine. J Pharm Pharmacol (1974) 0.99
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol (1998) 0.98
Myasthenia gravis: clinical and histological features in relation to thymectomy. J Neurol Neurosurg Psychiatry (1976) 0.96
Anatomical and electrophysiological studies on the reciprocal projections between the subthalamic nucleus and nucleus tegmenti pedunculopontinus in the rat. Neuroscience (1983) 0.96
Cerebrospinal fluid absorption in primary hypoparathyroidism. J Neurol Neurosurg Psychiatry (1977) 0.95
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol (1999) 0.95
Effects of manipulating pallidal and nigral GABA on striatally-mediated head-turning in the rat [proceedings]. Br J Pharmacol (1977) 0.95
The effect of bicuculline on the gamma-aminobutyric acid (GABA) receptors of neurons of Periplaneta americana and Helix aspersa. Brain Res (1971) 0.93
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.92
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord (1991) 0.92
Identification of different subpopulations of neostriatal neurones projecting to globus pallidus or substantia nigra in the monkey: a retrograde fluorescence double-labelling study. Neurosci Lett (1984) 0.90
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord (2001) 0.90
Proceedings: Pharmacological studies on single neurones in the substantia nigra of the rat. Br J Pharmacol (1974) 0.89
Nucleus tegmenti pedunculopontinus: efferent connections with special reference to the basal ganglia, studied in the rat by anterograde and retrograde transport of horseradish peroxidase. Neuroscience (1983) 0.89
Convergent synaptic input from the neostriatum and the subthalamus onto identified nigrothalamic neurons in the rat. Eur J Neurosci (1994) 0.88
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord (1999) 0.88
On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol (1994) 0.87
The effect of morphine on turning behaviour in rats and mice with unilateral 6-hydroxydopamine lesions [proceedings]. Br J Pharmacol (1976) 0.87
Basal ganglia and other afferent projections to the peribrachial region in the rat: a study using retrograde and anterograde transport of horseradish peroxidase. Neuroscience (1981) 0.87
Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology (1985) 0.87
The relationship between cerebrospinal fluid and plasma electrolytes in patients with meningitis. J Neurol Sci (1974) 0.86
Induction of chorea and dystonia in parkinsonian primates. Mov Disord (1990) 0.86
Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res (1993) 0.86
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol (2001) 0.86
Picrotoxin antagonism of gamma-aminobutyric acid inhibitory responses and synaptic inhibition in the rat substantia nigra. Br J Pharmacol (1973) 0.86
Anatomic localization of dyskinesia in children with "profound" perinatal hypoxic-ischemic injury. AJNR Am J Neuroradiol (2009) 0.86
Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res (1989) 0.85
Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate. Br J Neurosurg (1992) 0.85
A method for investigating neurotransmission in the basal ganglia using combined stimulation and intracerebral drug injection [proceedings]. Br J Pharmacol (1977) 0.85
Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J (2001) 0.85
The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain (1989) 0.85
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp Neurol (1997) 0.85
Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res (1990) 0.84
Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci Lett (1985) 0.84
Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the rat. Brain Res (1992) 0.84
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci (1989) 0.84
Further evidence for the stimulation of rat brain dopamine receptors by ergometrine. J Pharm Pharmacol (1974) 0.84
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol (2001) 0.84
Experimental choreoathetosis produced by injection of a gamma-aminobutyric acid antagonist into the lentiform nucleus in the monkey. Neurosci Lett (1984) 0.84
Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neurosci Lett (1986) 0.84
[3H]-2-deoxyglucose uptake study in mutant dystonic hamsters: abnormalities in discrete brain regions of the motor system. Mov Disord (1998) 0.83
Subthalamic nucleus efferent projection to the cerebral cortex. Neuroscience (1981) 0.83
A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neurosci Lett (1994) 0.83
Metabolic studies in subarachnoid haemorrhage and strokes. I. Serial changes in acid-base values in blood and cerebrospinal fluid. Brain (1973) 0.83
Neurons projecting from the entopeduncular nucleus to the thalamus receive convergent synaptic inputs from the subthalamic nucleus and the neostriatum in the rat. Brain Res (1994) 0.82
Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord (1990) 0.82
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci (1987) 0.82
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease. Exp Neurol (1996) 0.82
The efferent projections of the nucleus accumbens in the rat. Brain Res (1977) 0.82
Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol (1996) 0.82
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Exp Neurol (2001) 0.81
Metabolic studies in subarachnoid haemorrhage and strokes. II. Serial changes in cerebrospinal fluid and plasma urea electrolytes and osmolality. Brain (1973) 0.81
Autoradiographic localization of dopamine D1 binding sites in areas receiving striatal input. Eur J Pharmacol (1987) 0.81
Experimental torticollis in the monkey produced by unilateral 6-hydroxy-dopamine brain lesions. Brain Res (1978) 0.81
The organisation of the efferent projections of the zona incerta. J Anat (1985) 0.80
Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Adv Neurol (1998) 0.80
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci (1987) 0.80